IP Library Granted Patent US 11,090,283
Granted Patent B2
US 11,090,283 · App. 15/361,049 · Granted Aug 17, 2021

Solid forms of selective androgen receptor modulators

Inventors: James T. Dalton (Ann Arbor, MI); Thomas G. Bird (Eads, TN); Tai Ahn (Ellicott City, MD); David A. Dickason (Cordova, TN); Seoung-Soo Hong (Collierville, TN)
Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
A61K31/277C07C253/30C07C255/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,283
App. No.
15/361,049
Granted
Aug 17, 2021
Kind
B2
Abstract

The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

Claims (4)

1. A method of treating a condition caused by androgen decline in aging male (ADAM) or androgen decline in female (ADIF) comprising administering a composition comprising a solid form D of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide compound, characterized by an X-ray powder diffraction pattern comprising unique peaks at °2θ (d value Å) angles of about 4.4 (19.9), 8.5 (10.4), 8.8 (10.0), 11.3 (7.8), 12.7 (6.9), 13.8 (6.4), 14.4 (6.1), 14.6 (6.0), 15.1 (5.8), 16.1 (5.5), 16.6 (5.3), 16.9 (5.2), 18.0 (4.9), 18.7 (4.7), 19.0 (4.6), 19.4 (4.55), 20.8 (4.25), 22.1 (4.0), 22.7 (3.9), 23.1 (3.8), 23.4 (3.8), 24.7 (3.6), 24.9 (3.56), 25.3 (3.51), 27.8 (3.2) and 29.3 (3.0).

2. The method of claim 1 , wherein said condition caused by androgen decline in aging male (ADAM) is selected from fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, benign prostate hyperplasia, and prostate cancer or any combination thereof.

3. The method of claim 1 , wherein said condition caused by androgen decline in female (ADIF) is selected from sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, depression, anemia, hair loss, obesity, endometriosis, uterine cancer, and ovarian cancer or any combination thereof.

4. A method of treating chronic muscular wasting comprising administering a composition comprising a solid form D of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide compound, characterized by an X-ray powder diffraction pattern comprising unique peaks at °2θ (d value Å) angles of about 4.4 (19.9), 8.5 (10.4), 8.8 (10.0), 11.3 (7.8), 12.7 (6.9), 13.8 (6.4), 14.4 (6.1), 14.6 (6.0), 15.1 (5.8), 16.1 (5.5), 16.6 (5.3), 16.9 (5.2), 18.0 (4.9), 18.7 (4.7), 19.0 (4.6), 19.4 (4.55), 20.8 (4.25), 22.1 (4.0), 22.7 (3.9), 23.1 (3.8), 23.4 (3.8), 24.7 (3.6), 24.9 (3.56), 25.3 (3.51), 27.8 (3.2) and 29.3 (3.0).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2020
From: ONCTERNAL THERAPEUTICS, INC.
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 054318/0958 →
CHANGE OF NAME Recorded Jul 4, 2019
From: GTX, INC.
To: ONCTERNAL THERAPEUTICS, INC
Reel/Frame 049679/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: DALTON, JAMES T.; BIRD, THOMAS G.; AHN, TAI; DICKASON, DAVID A; HONG, SEOUNG-SOO
To: GTX, INC.
Reel/Frame 044023/0315 →
Continuity (7)
Continuation 14875181 · Oct 5, 2015
Continuation 14058896 · Oct 21, 2013
Division 13153427 · Jun 5, 2011
Division 12228100 · Sep 29, 2008
Continuation In Part 12209137 · Sep 11, 2008
Provisional Application 60960012 · Sep 11, 2007
Related Publication 20170266149A1 · Sep 21, 2017